ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 612,63
0,19%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Prime Medicine Inc (PRME)

  7. Prime Medicine Inc (PRME) Actualités

PRME

Prime Medicine (PRME)

Prime Medicine Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRME
DateHeureSourceTitreSymboleSociété
30/05/202414h00GlobeNewswire Inc.Prime Medicine to Present at Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
21/05/202422h06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PRMEPrime Medicine Inc
21/05/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
13/05/202414h00GlobeNewswire Inc.Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:PRMEPrime Medicine Inc
10/05/202414h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRMEPrime Medicine Inc
10/05/202414h00GlobeNewswire Inc.Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
08/05/202414h00GlobeNewswire Inc.Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
01/05/202414h00GlobeNewswire Inc.Prime Medicine to Participate in the 27th Annual Milken Institute Global ConferenceNASDAQ:PRMEPrime Medicine Inc
29/04/202413h00GlobeNewswire Inc.Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
23/04/202414h00GlobeNewswire Inc.Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsNASDAQ:PRMEPrime Medicine Inc
01/03/202414h09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRMEPrime Medicine Inc
01/03/202414h04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRMEPrime Medicine Inc
01/03/202414h00GlobeNewswire Inc.Prime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
28/02/202414h00GlobeNewswire Inc.Prime Medicine to Participate in Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
23/02/202423h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
23/02/202403h31Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PRMEPrime Medicine Inc
20/02/202422h01GlobeNewswire Inc.Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:PRMEPrime Medicine Inc
16/02/202412h17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
15/02/202405h50GlobeNewswire Inc.Prime Medicine Announces Pricing of Upsized Public OfferingNASDAQ:PRMEPrime Medicine Inc
15/02/202403h57Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PRMEPrime Medicine Inc
14/02/202422h05GlobeNewswire Inc.Prime Medicine Announces Proposed Public Offering of Common StockNASDAQ:PRMEPrime Medicine Inc
25/01/202414h00GlobeNewswire Inc.Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic FibrosisNASDAQ:PRMEPrime Medicine Inc
05/01/202414h00GlobeNewswire Inc.Prime Medicine Appoints Allan Reine, M.D., as Chief Financial OfficerNASDAQ:PRMEPrime Medicine Inc
02/01/202414h00GlobeNewswire Inc.Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PRMEPrime Medicine Inc
14/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRMEPrime Medicine Inc
03/11/202322h23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PRMEPrime Medicine Inc
03/11/202321h01GlobeNewswire Inc.Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
27/10/202312h00GlobeNewswire Inc.Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1bNASDAQ:PRMEPrime Medicine Inc
24/10/202313h30GlobeNewswire Inc.Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological DiseasesNASDAQ:PRMEPrime Medicine Inc
17/10/202314h00GlobeNewswire Inc.Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry ConferencesNASDAQ:PRMEPrime Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:PRME

Dernières Valeurs Consultées

LSE
48FI
Investec Bnk 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés